News for April 2007
The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent agency funded by Canadian federal, provincial, and territorial governments to provide health care decision makers with credible, impartial advice and information about the effectiveness and efficiency of drugs and other health technologies. Unlike regulators who determine which technologies can be used in Canada, CADTH supports decision makers who are exploring what technologies should be used to achieve the best outcomes both on patient health and the health care system.
For details on how to contact CADTH, visit our Contact Us page.
CADTH Participation in Standing Committee on Health Study of CDR
April 26, 2007
The House of Commons Standing Committee on Health is conducting a study to examine the status of and progress accomplished under the Common Drug Review (CDR).CADTH Submission to the Standing ...
CADTH Releases Intervention Tools aimed at influencing behaviour, regarding the prescribing and use of Proton Pump Inhibitors
April 25, 2007
OTTAWA — The Canadian Agency for Drugs and Technologies in Health (CADTH) today announced the release of Optimal Therapy Reports and Intervention Tools for the prescribing and use of ...
CADTH releases an Optimal Therapy Report on Proton Pump Inhibitors (PPIs) relating to the economic component of the COMPUS PPI Project.
April 13, 2007
CADTH Announces Expansion of Common Drug Review (CDR) Program
April 12, 2007
CDR to be expanded to new indications for old drugsThe Canadian Agency for Drugs and Technologies in Health (CADTH) today announced that it has received approval and funding from federal, ...
CADTH Announces Partners in Health Technology Assessment (PIHTA)
April 05, 2007
The Canadian Agency for Drugs and Technologies in Health (CADTH) today announced the selection of McMaster University’s Network of Excellence for the Assessment of Health Technologies ...